Literature DB >> 28000322

Head-drop: A frequent feature of late-onset myasthenia gravis.

Marvin Sih1, Betty Soliven1, Nicholas Mathenia1, John Jacobsen1, Kourosh Rezania1.   

Abstract

INTRODUCTION: Head-drop is often encountered in myasthenia gravis (MG) patients, but its frequency and clinical course have not been studied systematically.
METHODS: In a retrospective study of a cohort of MG patients seen over a period of 11 years in a tertiary medical center, we assessed the clinical characteristics of patients who had head-drop.
RESULTS: Of 146 generalized MG patients, 15 had head-drop during the course of their disease. Head-drop patients had older age of onset than those who did not have head-drop (mean age of onset 59.1 vs. 42.3 years) and were predominantly men. Head-drop was present in 23% of patients > 60 versus 6% of those < 60 years, and it improved in 9 of 11 patients with treatment directed to generalized MG.
CONCLUSIONS: Head-drop is a common, treatment-responsive manifestation of late-onset MG. Muscle Nerve 56: 441-444, 2017.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  MuSK; acetylcholine receptor antibody; dropped head; head-drop; late-onset; myasthenia gravis; respiratory weakness

Mesh:

Year:  2017        PMID: 28000322     DOI: 10.1002/mus.25526

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

1.  New Daily Persistent Headache-like Presentation Triggered by a Sudden Head Drop in a Patient With Myasthenia Gravis.

Authors:  Upinder K Dhand
Journal:  Neurol Clin Pract       Date:  2021-10

Review 2.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 3.  Immunotherapy in myasthenia gravis in the era of biologics.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

4.  Dropped head syndrome due to neuromuscular disorders: Clinical manifestation and evaluation.

Authors:  Ahmet Z Burakgazi; Perry K Richardson; Mohammad Abu-Rub
Journal:  Neurol Int       Date:  2019-06-19

5.  Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.

Authors:  Je-Seong Kim; Tai-Seung Nam; Jieun Kim; Bo-Gun Kho; Cheol-Kyu Park; In-Jae Oh; Young-Chul Kim
Journal:  Thorac Cancer       Date:  2019-08-21       Impact factor: 3.500

Review 6.  Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic.

Authors:  Dario Ricciardi; Silvia Casagrande; Francesco Iodice; Bianca Orlando; Francesca Trojsi; Giovanni Cirillo; Marinella Clerico; Marco Bozzali; Letizia Leocani; Gianmarco Abbadessa; Giuseppina Miele; Gioacchino Tedeschi; Simona Bonavita; Luigi Lavorgna
Journal:  Neurol Sci       Date:  2021-08-26       Impact factor: 3.307

7.  Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.

Authors:  Sijia Zhao; Xu Yan; Jiaqi Ding; Kaixi Ren; Shuyu Sun; Jiarui Lu; Chao Zhang; Kai Zhang; Zhuyi Li; Jun Guo
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.